iiinova — where your digital self keeps evolving

SWOG Cancer Research Network @swog.org · 29/05/2026

Lung-MAP investigators present 4 posters at #ASCO26. 1 is an analysis led by Dr. Diane Tseng of how the severity of immune-related adverse events (irAEs) in patients getting ICIs is associated with clinical outcomes: www.asco.org/abstracts-pr...

030

SWOG Cancer Research Network @swog.org · 28/05/2026

SWOG researchers give #ASCO26 oral presentations on results of 2 GI trials, a testicular cancer study, work on vit D & neuropathy, big-picture results from S1609 DART rare cancers trial, & an AI prediction model in breast cancer! @swog.org ASCO calendar is at swog.org/media/26051.

022

SWOG Cancer Research Network @swog.org · 01/04/2026

S2409 PRISM is testing whether it’s feasible to identify each patient’s small cell #LungCancer subtype and use that information to select the best therapy for that patient. #SCLC Co-PI: Alberto Chiappori, MD @moffittnews.bsky.social swog.org/clinical-trials/S2409

020

SWOG Cancer Research Network @swog.org · 24/03/2026

Blog post from SWOG chairs @drdawnhershman.bsky.social & Primo N. Lara, MD: SWOG Establishes An APP & Nurse Scientist Cmte Our new cmte recognizes the contributions of APPs to our success & will help empower more of them to contribute to their full scope of practice. www.swog.org/news-events/...

011

SWOG Cancer Research Network @swog.org · 19/03/2026

Front Line post from @swog.org group chairs @drdawnhershman.bsky.social & Primo N. Lara, MD: The Next Era of SWOG Success In our vision, we focus even more intensively on studies that tackle the vital questions only public-powered research will answer. www.swog.org/news-events/...

012

SWOG Cancer Research Network @swog.org · 09/03/2026

Our @swog.org Chairs' blog: A Team Science Leadership Team SWOG is all about interdisciplinary collaboration and team science. We think a leadership approach with dual principal investigators who bring complementary skillsets and expertise to the role is a great fit. www.swog.org/news-events/...

021

SWOG Cancer Research Network @swog.org · 04/03/2026

Saying Thank You: Dr. Charles Blanke's last Front Line post as chair of @swog.org: "I have been honored to serve as chair of this research group over the last 13 years, and I could not be prouder of what you have accomplished in that time." www.swog.org/news-events/...

021

SWOG Cancer Research Network @swog.org · 25/02/2026

Registration is open for SWOG's spring group meeting, April 30-May 2, in San Francisco! Incoming Group Chairs Drs. Primo Lara, Jr., & Dawn Hershman invite SWOG members to bring questions, concerns, & ideas to an interactive town hall-style plenary, Friday, May 1, 2-4pm PT. Details: swog.org/Sp26mtg

100

SWOG Cancer Research Network @swog.org · 12/01/2026

S2213 is a randomized ph 3 to definitively learn role of transplant in pts newly diagnosed w AL #amyloidosis. BMT-CTN Champion: Anita D'Souza, MD SWOG.org/clinical-trials/S2213

020

SWOG Cancer Research Network @swog.org · 09/01/2026

Treated for muscle invasive bladder cancer and want to keep your bladder? Ask your doctor about #ClinicalTrial S2427 (BRIGHT). SWOG.org/S2427. 1-800-4-CANCER. #KeepMyBladder #MIBC

000

SWOG Cancer Research Network @swog.org · 08/01/2026

Extensive stage small cell lung cancer can be hard to treat — but study S2409 (the PRISM trial) is looking for better, personalized options. To learn more, visit SWOG.org/S2409 or call 1-800-4-CANCER. #LCSM #SCLC

000

SWOG Cancer Research Network @swog.org · 06/01/2026

S2213 is an #ALamyloidosis #clinicaltrial to determine if Dara-VCD drug treatment or stem cell transplant is better for patients. The study may be an option for you if your treatment plan could safely include a stem cell transplant. Learn more at SWOG.org/S2213. Or call 1-800-4- CANCER.

000

SWOG Cancer Research Network @swog.org · 02/01/2026

#ClinicalTrial S2409 (PRISM) asks if it’s possible to personalize treatment for extensive stage small cell lung cancer. It compares standard treatment alone to standard treatment plus a drug matched to the cancer subtype. Learn more: SWOG.org/S2409 or 1-800-4-CANCER.

010

SWOG Cancer Research Network @swog.org · 01/01/2026

Have you had treatment for muscle invasive #BladderCancer? Are you expecting surgery next? If your scans show no cancer, you may be able to join #ClinicalTrial S2427 (also called BRIGHT). Visit SWOG.org/S2427 to learn more. Or call 1-800-4-CANCER. #BladderPreservation

010

SWOG Cancer Research Network @swog.org · 30/12/2025

Just activated! #NCTN S2433 trial is enrolling patients with locally advanced or metastatic #pancreatic ductal adenocarcinoma without KRAS or BRAF V600E mutations. Randomized to physician’s choice SOC w/wo panitumumab. #pancsm PI: Rachael A. Safyan, MD @fredhutch.org swog.org/clinical-tri...

011

SWOG Cancer Research Network @swog.org · 29/12/2025

S2213 is a randomized ph 3 to definitively learn the role of transplant in pts newly diagnosed w AL #amyloidosis. ECOG-ACRIN Cancer Research Group Champion: Taxiarchis Kourelis, MD SWOG.org/clinical-trials/S2213

010

SWOG Cancer Research Network @swog.org · 24/12/2025

Bladder removal surgery can have a big impact on quality of life. Study S2427 (also called BRIGHT) is testing a possible #BladderSparing approach for people with muscle invasive #BladderCancer. To learn more, visit SWOG.org/S2427 or call 1-800-4-CANCER. #MIBC

000

SWOG Cancer Research Network @swog.org · 23/12/2025

If you have extensive stage small cell lung cancer (ES-SCLC) and you haven’t started initial treatment, ask your doctor about study S2409 (PRISM). It tests the cancer for certain features to match patients with treatments. SWOG.org/S2409. 1-800-4-CANCER. #LCSM #SCLC

000

SWOG Cancer Research Network @swog.org · 22/12/2025

Study S2213 asks if a drug combination known as Dara-VCD or stem cell transplant is better for treating AL #amyloidosis. It tests how well the treatments work, and how they affect quality of life. Learn more at SWOG.org/S2213. Or call 1-800-4-CANCER. #raredisease #clinicaltrial

000

SWOG Cancer Research Network @swog.org · 19/12/2025

Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD: FDA–AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Optimized Dosages for Registrational Trials doi.org/10.1158/1078...

010

SWOG Cancer Research Network @swog.org · 19/12/2025

#ClinicalTrial S2409 PRISM randomizes patients with extensive stage small cell lung cancer to durvalumab with or without a drug that’s targeted to their specific #SCLC subtype. Co-PI: Nan Sethakorn, MD, PhD - Loyola Univ Medical Center swog.org/clinical-trials/S2409

010

SWOG Cancer Research Network @swog.org · 18/12/2025

S2427 BRIGHT trial tests IO + RT as bladder-preserving tx for patients with MIBC who respond to NAT. PROs track QoL and treatment-related symptomatic toxicities. Systematic biopsies needed at post-NAT TURBT. Co-PI: James B. Yu, MD, MHS, Dartmouth Cancer Center swog.org/clinical-trials/S2427

000

SWOG Cancer Research Network @swog.org · 17/12/2025

If you have extensive stage small cell lung cancer (ES-SCLC) and you haven’t finished initial treatment, ask your doctor about study S2409 (PRISM). It tests the cancer for certain features to match patients with treatments. SWOG.org/S2409. 1-800-4-CANCER. #LCSM #SCLC

000

SWOG Cancer Research Network @swog.org · 16/12/2025

Are you getting treatment for muscle invasive bladder cancer? Ask your doctor about S2427 (BRIGHT). It’s a #ClinicalTrial testing whether an immunotherapy drug plus radiation therapy can help patients keep their bladder. SWOG.org/S2427. 1-800-4-CANCER. #MIBC

001

SWOG Cancer Research Network @swog.org · 15/12/2025

What’s the best consolidation tx for patients newly diagnosed with #ALamyloidosis: #StemCellTransplant w melphalan? Or daratumumab + VCD? Trial S2213 also compares minimal residual disease negativity rates. TM Co-PI: Brian Walker, PhD - Indiana Univ School of Medicine SWOG.org/clinical-trials/S2213

010

SWOG Cancer Research Network @swog.org · 12/12/2025

Are you starting treatment for #ALAmyloidosis? Ask your doctor about #clinicaltrial S2213. It compares using a drug combination called Dara-VCD vs. stem cell transplant. Learn more at SWOG.org/S2213. Or call 1-800-4-CANCER. #raredisease

000

SWOG Cancer Research Network @swog.org · 11/12/2025

The S2409 PRISM trial biomarker-tests patients with extensive stage small cell #LungCancer during induction treatment and assigns them to 1 of 3 maintenance therapy cohorts based on #SCLC subtype and SLFN11 status. #LCSM Co-PI: So Yeon Kim, MD Yale Cancer Center swog.org/clinical-trials/S2409

001

SWOG Cancer Research Network @swog.org · 10/12/2025

S2427 BRIGHT tests IO + RT as bladder-preserving treatment for patients with #MIBC who respond to NAT. Focal, non-diffuse carcinoma in situ (CIS) is allowed. Systematic biopsies needed at post-NAT TURBT. Co-PI: Daniel A. Hamstra, MD, PhD Baylor College of Medicine swog.org/clinical-trials/S2427

000

SWOG Cancer Research Network @swog.org · 09/12/2025

AL #amyloidosis trial S2213 compares autologous transplant to Dara-VCD consolidation. Also compares post-consolidation #PatientReportedOutcomes for physical function and other #HRQoL measures. QoL/PRO Co-PI: Terri Parker, MD Yale Cancer Center SWOG.org/clinical-trials/S2213

010

SWOG Cancer Research Network @swog.org · 08/12/2025

S2427 (BRIGHT) is a study for people who were treated for muscle invasive #BladderCancer — and the cancer shrunk or can’t be found after treatment. The study asks if a drug plus radiation can help prevent bladder removal. Visit SWOG.org/S2427. Or call 1-800-4-CANCER.

010

SWOG Cancer Research Network @swog.org · 08/12/2025

S2409 (the PRISM trial) is a study for people with extensive stage small cell lung cancer (ES-SCLC). The goal is to match different #SCLC subtypes with the best treatment. Visit SWOG.org/S2409. Or call 1-800-4-CANCER. #LCSM

020

SWOG Cancer Research Network @swog.org · 05/12/2025

Enrolling: SWOG S2213 in newly diagnosed #ALamyloidosis. Daratumumab + VCD induction, then randomization to autologous stem cell transplant or Dara-VCD consolidation. Patients on both arms get dara maintenance. Co-PI: @surbhisidanamd.bsky.social Stanford Medicine SWOG.org/clinical-trials/S2213

000

SWOG Cancer Research Network @swog.org · 03/12/2025

#Clinicaltrial S2213 asks if a drug combination (called Dara-VCD) or stem cell transplant is better for people with AL #amyloidosis. The trial is for people who haven’t started treatment yet. Learn more at SWOG.org/S2213. Or call 1-800-4-CANCER.

010

SWOG Cancer Research Network @swog.org · 02/12/2025

S2409 PRISM is testing whether it’s feasible to identify each patient’s small cell #LungCancer subtype and use that information to select the best therapy for that patient. #SCLC Co-PI: Alberto Chiappori, MD Moffitt Cancer Center swog.org/clinical-trials/S2409

011

SWOG Cancer Research Network @swog.org · 01/12/2025

If patients w #MIBC have a clinically sig response to NAT, is cystectomy needed? S2427 BRIGHT trial tests whether pembro + RT can let patients keep their bladder. Systematic biopsies needed at post-NAT TURBT. Co-PI: Abhishek Tripathi, MD City of Hope swog.org/clinical-trials/S2427

021

SWOG Cancer Research Network @swog.org · 01/12/2025

The NCI myeloMATCH precision medicine trial portfolio in myeloid cancers is highlighted in numerous presentations at the upcoming #ASH25 meeting. Learn more: dctd.cancer.gov/about/news-e... @swog.org @eaonc.bsky.social @cctg.bsky.social #NCORP

032

SWOG Cancer Research Network @swog.org · 28/11/2025

Our @swog.org group chair's Front Line blog: Thank You Through a year that’s had more than its share of uncertainties, I’m thankful for you, SWOG’s members and supporters, for all you do to care for our patients and advance our research. www.swog.org/news-events/...

000

SWOG Cancer Research Network @swog.org · 28/11/2025

Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD: CAR-T Cells in Solid Tumors: Challenges and Breakthroughs doi.org/10.1016/j.xc...

000

SWOG Cancer Research Network @swog.org · 26/11/2025

Study S2213 is for people with newly diagnosed #ALAmyloidosis. It compares a combination of immunotherapy and chemo drugs (called Dara-VCD) to stem cell transplant. Learn more at SWOG.org/S2213. Or call 1-800-4-CANCER. Ask about S2213. #raredisease #mmsm

000

SWOG Cancer Research Network @swog.org · 25/11/2025

S2427 BRIGHT trial: In patients with #MIBC, can immunoradiotherapy after response to neoadj therapy (cT0/cT1) allow for bladder preservation? Systematic biopsies needed at post-NAT TURBT pre-registration. Co-PI: S. Daneshmand, MD USC Norris Comprehensive Cancer Center swog.org/clinical-trials/S2427

011

SWOG Cancer Research Network @swog.org · 24/11/2025

The S2409 PRISM #ClinicalTrial asks if we can treat extensive stage small cell lung cancer more effectively by targeting the vulnerabilities of specific molecular subtypes of the disease. #SCLC #LCSM PI: Anne Chiang, MD, PhD - Yale Cancer Center swog.org/clinical-trials/S2409

011

SWOG Cancer Research Network @swog.org · 22/11/2025

Consider S2427 BRIGHT for your pts with #MIBC getting neoadj therapy. If systematic biopsies at post-NAT TURBT show cT0 or cT1, pt may be eligible for S2427. Can IO + RT be bladder-preserving? #BladderCancer PI: Leslie Ballas, MD Cedars-Sinai Cancer swog.org/clinical-trials/S2427

011

SWOG Cancer Research Network @swog.org · 14/11/2025

Our #TranslationalMedicine Link of the Week, chosen by @SWOG's @recnac1 & Jimmy Rae, PhD: Targeting DNA Repair Mechanisms in Cancer Therapy: The Role of Small Molecule DNA Repair Inhibitors academic.oup.com/narcancer/ar...

000

SWOG Cancer Research Network @swog.org · 07/11/2025

From our @swog.org group chair's Front Line blog: Stories of SWOG Accrual Stars We have many inspiring stories of members and sites going above and beyond to enroll robustly to our trials. www.swog.org/news-events/...

000

SWOG Cancer Research Network @swog.org · 06/11/2025

Lung-MAP 3.0’s easier genetic screening process means the Lung-MAP trial will be even better positioned to enroll a group of patients fully representative of the population of patients with advanced #NSCLC in the U.S. lung-map.org @focr.bsky.social @swog.org

011

SWOG Cancer Research Network @swog.org · 04/11/2025

Our @swog.org group chair's Front Line blog: Group Meeting Surveys: You "Talk," We Listen SWOG has now held 2 group meetings under the new 3-day model (trimmed from 4 days previously). What do the surveys say? www.swog.org/news-events/...

001

SWOG Cancer Research Network @swog.org · 31/10/2025

Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD: Navigating Cancer Complexity: Integrative Multi-Omics Methodologies for Clinical Insights doi.org/10.1177/1179...

010

SWOG Cancer Research Network @swog.org · 27/10/2025

Our @swog.org group chair's Front Line blog: SWOG Research Demonstrates the Special Role of Federal Sponsorship Presentation at #ASCOQLTY25 provides yet more evidence of the essential role of federal support in cancer research. www.swog.org/news-events/...

000

SWOG Cancer Research Network @swog.org · 17/10/2025

The S2409 PRISM #ClinicalTrial asks if we can treat extensive stage small cell lung cancer more effectively by targeting the vulnerabilities of specific molecular subtypes of the disease. #SCLC #LCSM PI: Anne Chiang, MD, PhD, Yale Cancer Center swog.org/clinical-trials/S2409

000

SWOG Cancer Research Network @swog.org · 17/10/2025

Our @swog.org group chair's blog: Welcoming SWOG’s New Myeloma Leader: Dr. Amrita Y. Krishnan I'm delighted to introduce Dr. Krishnan as new chair of SWOG’s Barlogie-Salmon myeloma committee, as of Nov 1! swog.org/news-events/...

000